Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 6/20 | 0.59 |
| ▸ | GSK3A | P49840 | 3/20 | 0.59 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.53 |
| ▸ | RGS4 | P49798 | 1/20 | 0.52 |
| ▸ | RGS8 | P57771 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | PRKCA | P17252 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13562488 | 0.79 | GSK3B (0.53) | GSK3BGSK3ARGS4RGS8TSHR | |
| SCHEMBL2107216 | 0.76 | GSK3B (1.00) | GSK3BGSK3AALKBH5RGS4RGS8 | |
| SCHEMBL18731445 | 0.75 | ALDH1A1 (0.43) | TSHRKDM4ECYP1A2CYP2C9CYP2C19 | |
| SCHEMBL15212631 | 0.72 | GSK3B (0.78) | GSK3BGSK3AALKBH5RGS4RGS8 | |
| SCHEMBL29239055 | 0.71 | GSK3B (0.76) | GSK3BGSK3AALKBH5RGS4RGS8 | |
| SCHEMBL15210819 | 0.70 | GSK3B (0.73) | GSK3BGSK3AALKBH5RGS4RGS8 | |
| SCHEMBL29239084 | 0.69 | GSK3B (0.72) | GSK3BGSK3AALKBH5RGS4RGS8 | |
| SCHEMBL28891765 | 0.69 | GSK3B (0.53) | GSK3BGSK3AALKBH5RGS4RGS8 | |
| SCHEMBL2107221 | 0.69 | RGS4 (1.00) | GSK3BGSK3AALKBH5RGS4RGS8 | |
| SCHEMBL29239098 | 0.69 | GSK3B (0.75) | GSK3BGSK3AALKBH5RGS4RGS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| EP-2838888-B1 | THIADIAZOLIDINEDIONES AS GSK-3 INHIBITORS | ASD THERAPEUTICS PARTNERS LLC (US) | 2017-04-12 | — | — | EP | disclosed |
| EP-2838888-B1 | THIADIAZOLIDINEDIONES AS GSK-3 INHIBITORS | ASD THERAPEUTICS PARTNERS LLC (US) | 2017-04-12 | — | — | EP | disclosed |
| US-9469618-B2 | Thiadiazolidinediones as GSK-3 inhibitors | ASD THERAPEUTICS PARTNERS, LLC (US) | 2016-10-18 | — | — | US | disclosed |
| US-9469618-B2 | Thiadiazolidinediones as GSK-3 inhibitors | ASD THERAPEUTICS PARTNERS, LLC (US) | 2016-10-18 | — | — | US | disclosed |
| US-9469618-B2 | Thiadiazolidinediones as GSK-3 inhibitors | ASD THERAPEUTICS PARTNERS, LLC (US) | 2016-10-18 | — | — | US | disclosed |
| US-20160257660-A1 | THIADIAZOLIDINEDIONES AS GSK-3 INHIBITORS | ASD THERAPEUTICS PARTNERS LLC (US) | 2016-09-08 | — | — | US | disclosed |
| US-20160257660-A1 | THIADIAZOLIDINEDIONES AS GSK-3 INHIBITORS | ASD THERAPEUTICS PARTNERS LLC (US) | 2016-09-08 | — | — | US | disclosed |
| US-20160257660-A1 | THIADIAZOLIDINEDIONES AS GSK-3 INHIBITORS | ASD THERAPEUTICS PARTNERS LLC (US) | 2016-09-08 | — | — | US | disclosed |
| US-9371299-B2 | Thiadiazolidinediones as GSK-3 inhibitors | ASD THERAPEUTICS PARTNERS, LLC (US) | 2016-06-21 | — | — | US | disclosed |
| US-9371299-B2 | Thiadiazolidinediones as GSK-3 inhibitors | ASD THERAPEUTICS PARTNERS, LLC (US) | 2016-06-21 | — | — | US | disclosed |
| US-9371299-B2 | Thiadiazolidinediones as GSK-3 inhibitors | ASD THERAPEUTICS PARTNERS, LLC (US) | 2016-06-21 | — | — | US | disclosed |
| EP-2838888-A1 | THIADIAZOLIDINEDIONES AS GSK-3 INHIBITORS | ASD Therapeutics Partners LLC (US) | 2015-02-25 | — | — | EP | disclosed |
| US-20150038538-A1 | THIADIAZOLIDINEDIONES AS GSK-3 INHIBITORS | ASD THERAPEUTICS PARTNERS LLC (US) | 2015-02-05 | — | — | US | disclosed |
| US-20150038538-A1 | THIADIAZOLIDINEDIONES AS GSK-3 INHIBITORS | ASD THERAPEUTICS PARTNERS LLC (US) | 2015-02-05 | — | — | US | disclosed |
| US-20150038538-A1 | THIADIAZOLIDINEDIONES AS GSK-3 INHIBITORS | ASD THERAPEUTICS PARTNERS LLC (US) | 2015-02-05 | — | — | US | disclosed |
| WO-2013124413-A1 | THIADIAZOLIDINEDIONES AS GSK-3 INHIBITORS | NOSCIRA, S.A. (ES) | 2013-08-29 | — | — | WO | disclosed |
| WO-2013124413-A1 | THIADIAZOLIDINEDIONES AS GSK-3 INHIBITORS | NOSCIRA, S.A. (ES) | 2013-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257660-A1 | THIADIAZOLIDINEDIONES AS GSK-3 INHIBITORS | GSK3B, GSK3A, GSKIP | GSK3B 1/4885GSK3A 2/4885ALKBH5 3601/4885 |
| US-20150038538-A1 | THIADIAZOLIDINEDIONES AS GSK-3 INHIBITORS | GSK3B, GSK3A, GSKIP | GSK3B 1/4885GSK3A 2/4885ALKBH5 3601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.